Overview Request Sample Pages Request Customization Download PDF
You are viewing: Mexico Companion Diagnostics Market analysis
Part of: Companion Diagnostics Market (Global)

The Mexico Companion Diagnostics Market was valued at $117.4 Million in 2026 and projected to reach to $163.7 Million by 2031, representing a compound annual growth rate of 11.4%. Mexico's companion diagnostics market is positioned for steady expansion as the country embraces precision medicine approaches in oncology and chronic disease management.

Mexico Companion Diagnostics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Mexico Companion Diagnostics Market Trends and Insights

  • Mexico is experiencing growing adoption of precision medicine and targeted therapies, driven by increasing healthcare investments and rising prevalence of chronic diseases including cancer.
  • The market in Mexico reflects broader Latin American trends toward personalized treatment approaches, supported by improving diagnostic infrastructure and regulatory frameworks that facilitate biomarker testing integration into clinical practice. The companion diagnostics sector in Mexico benefits from expanding pharmaceutical partnerships and growing awareness among healthcare providers of the clinical and economic value of diagnostic-guided treatment selection.
  • Mexico's market growth is underpinned by rising patient populations requiring oncology and other specialty care, coupled with enhanced reimbursement pathways for companion diagnostic tests.
  • Between 2026 and 2031, Mexico is expected to see accelerated adoption of next-generation sequencing and immunohistochemistry-based diagnostics, positioning the country as a key growth market within Latin America's companion diagnostics landscape..

Key Market Statistics

  • CAGR (2026-2031) 11.4% CAGR
  • Market Size, 2026 ~USD 117.4 Million
  • Forecast, 2031 ~USD 163.7 Million
  • Country Mexico

Mexico Companion Diagnostics Market Overview

Market Valuation Growth :

Mexico's companion diagnostics market is valued at USD 117.4 million in 2026 and is projected to grow to USD 163.7 million by 2031, representing a robust 11.4% CAGR over the forecast period.

Precision Medicine Adoption :

Mexico is experiencing accelerating adoption of precision medicine and targeted therapies, driven by healthcare modernization initiatives and increased awareness among oncology and specialty care providers.

Chronic Disease Prevalence :

Rising incidence of cancer and other chronic diseases in Mexico is fueling demand for companion diagnostics to enable personalized treatment selection and improve patient outcomes.

Healthcare Investment Expansion :

Increased government and private sector healthcare investments in Mexico are strengthening diagnostic infrastructure and expanding access to advanced companion diagnostic testing capabilities.

Mexico Companion Diagnostics Market Dynamics

  • Growing healthcare investments, coupled with rising cancer prevalence, are creating favorable conditions for market growth.
  • The Mexican healthcare system is increasingly recognizing the value of companion diagnostics in optimizing treatment efficacy and reducing adverse outcomes. The 11.4% CAGR through 2031 reflects Mexico's gradual but consistent shift toward personalized medicine.
  • Key drivers include improved diagnostic infrastructure, rising patient awareness, and expanding reimbursement coverage for targeted therapies.
  • As Mexico continues to align with global precision medicine standards, companion diagnostics adoption will accelerate across major metropolitan areas and secondary cities..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Mexico's companion diagnostics market is valued at USD 117.4 million in 2026 and is projected to grow to USD 163.7 million by 2031, representing an 11.4% CAGR.
      • Mexico is witnessing increased adoption of precision medicine and targeted therapies, supported by improving diagnostic infrastructure and regulatory frameworks.
      • The market in Mexico is driven by rising prevalence of chronic diseases, expanding pharmaceutical partnerships, and enhanced reimbursement pathways for diagnostic tests.
      • Mexico is expected to accelerate adoption of advanced diagnostic technologies including next-generation sequencing and immunohistochemistry between 2026 and 2031.

      Companion Diagnostics Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment NEXT-GENERATION SEQUENCING (Technology)
      Forecast Period 2026–2031
      Growth Rate CAGR of 12.9% from 2026 to 2031
      Largest Segment CANCER (Indication)
      Market Size Base Year (Billions) ~USD 6.31 (2026)
      Revenue Forecast (Billions) ~USD 11.57 (2031)
      Segments Covered Product & Service, Technology, Indication, Type, Sample Type, End User

      Mexico Companion Diagnostics Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Product & Service

      • Assays, Kits, And Reagents
      • Instruments & Systems
      • Software & Services

      By Technology

      • Immunohistochemistry
      • In Situ Hybridization
      • Next-Generation Sequencing
      • Other Technologies
      • Polymerase Chain Reaction

      By Indication

      • Cancer
      • Cardiovascular Diseases
      • Infectious Diseases
      • Neurological Diseases
      • Other Indications

      By Type

      • Blood Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
      • Other Cancer Types
      • Other Cancers

      By Sample Type

      • Blood Samples
      • Other Sample Types
      • Tissue Samples

      By End User

      • Contract Research Organizations
      • Other End Users
      • Pharmaceutical & Biopharmaceutical Companies
      • Pharmaceutical & Biotechnology Companies
      • Reference Laboratories

      Target Audience

      • Diagnostic Companies & IVD Manufacturers : Evaluate Mexico as a market opportunity for companion diagnostic product launches, assess competitive positioning, and identify optimal go-to-market strategies for precision medicine solutions.
      • Pharmaceutical & Biotech Firms : Understand companion diagnostics adoption rates for targeted therapies in Mexico to support clinical trial planning, regulatory submissions, and commercial strategies for oncology and specialty drugs.
      • Healthcare Investors & Private Equity : Assess investment opportunities in Mexico's companion diagnostics ecosystem, including diagnostic labs, precision medicine platforms, and healthcare technology companies with growth potential.
      • Healthcare Providers & Hospital Networks : Identify companion diagnostics adoption trends and best practices in Mexico to enhance precision medicine capabilities, improve patient outcomes, and optimize treatment selection processes.
      • Market Research & Consulting Firms : Leverage Mexico-specific market data and insights to support client advisory services, competitive analysis, and strategic planning in the companion diagnostics and precision medicine sectors.

      Key Companies in the Mexico Companion Diagnostics Market

      CompanyHQOwnershipStrongest segments
      CLARITY PHARMACEUTICALSAustraliaPublic CompanySAR-bisPSMA theranostic platform,SAR-Bombesin pan-cancer theranostics,SARTATE (SSTR2-targeted theranostics),
      FOUNDATION MEDICINEUnited StatesPrivate CompanyFoundationOne CDx (tissue-based solid tumor CGP),FoundationOne Liquid CDx (blood-based solid tumor CGP),Hematologic malignancy / sarcoma / other LDTs,
      GEUnited StatesPublic CompanyCommercial Engines & Services,Defense & Propulsion Technologies,
      GENOMIC HEALTH INCUnited StatesPrivate CompanyOncotype DX Breast Recurrence Score and related breast assays,Oncotype DX Colon and prostate cancer assays,Other genomic and emerging epigenomic decision-support services,
      MEDICAL & BIOLOGICAL LABORATORIES CO.JapanPrivate CompanyAllergy in vitro diagnostics,Autoimmune and skin disease diagnostics,COVID-19 and respiratory diagnostics,
      ROSETTA GENOMICSIsraelPublic CompanymicroRNA-based oncology tests (RosettaGX Cancer Origin, mi-KIDNEY, RosettaGX Reveal, mi-LUNG),FISH-based assays (UroVysion, ERG/PTEN, ALK/ROS1),PCR gene mutation analysis (bladder, lung, colon, melanoma),
      TOSOH CORPORATIONJapanPublic CompanyBasic chemicals and chlor-alkali (caustic soda, sodium bicarbonate, related),Vinyls and petrochemicals (VCM, ethylene, propylene, aromatics, EDC),Polymers and synthetic rubbers (EVA, PE, functional polymers, PVC pastes),
      DIASORINItalyPublic CompanyImmunodiagnostics (LIAISON XL / LIAISON XS),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other IVD solutions,
      GE HEALTHCAREUnited StatesPublic CompanyImaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS),
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products (lab, transfusion, molecular, point-of-care, rapid tests),Medical Devices (cardiovascular, diabetes care, neuromodulation, vascular, structural heart),Nutritional Products (pediatric, adult, infant formula),
      DANAHERUnited StatesPublic CompanyBiotechnology (Bioprocessing & Single-Use),Life Sciences Tools & Genomics,Diagnostics,
      GUARDANT HEALTHUnited StatesPublic CompanyGuardant360 portfolio (CDx, Liquid, Tissue),Shield colorectal cancer screening,Minimal residual disease and recurrence (Guardant Reveal),
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables,
      BIOMéRIEUXFrancePublic CompanyBIOFIRE & SPOTFIRE multiplex/lowplex PCR,VITEK (2, MS, REVEAL) ID/AST systems,BACT/ALERT VIRTUO & blood culture,
      ICON PLCIrelandPublic CompanyFull-service clinical development (Phase I–IV, peri/post-approval),Functional service partnerships & contract staffing,Laboratory, bioanalytical, biomarker, and vaccine testing,
      MYRIAD GENETICS, INC.United StatesPublic CompanyHereditary and oncology diagnostics (MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Women’s health and reproductive genetics (Prequel, Foresight, SneakPeek, FirstGene),Pharmacogenomics and mental health (GeneSight Psychotropic),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx and related),Coagulation diagnostics,Blood gas, electrolyte, and urinalysis systems,
      ABNOVA CORPORATIONTaiwanPublic CompanyAntibodies (mono/polyclonal, recombinant, circulating rare cell),Proteins/Peptides, Lysates/Slides, Beads/Dyes, Ab Arrays,Medical Diagnostic Instruments, Systems, and Automation,

      CLARITY PHARMACEUTICALS

      Clarity Pharmaceuticals is an Australian public company founded in 2010 that employs 88 people. The company operates in the pharmaceutical sector.

      FOUNDATION MEDICINE

      Foundation Medicine is a United States-based private company established in 2009 with 662 employees. The company operates in the pharmaceutical and biotechnology industry.

      GE

      GE is a United States public company founded in 1892 with 57,000 employees. The company is a diversified conglomerate operating across multiple industrial sectors.

      GENOMIC HEALTH INC

      Genomic Health Inc. is a United States-based private company founded in 2000 with 829 employees. The company operates in the genomics and biotechnology sector.

      MEDICAL & BIOLOGICAL LABORATORIES CO.

      Medical & Biological Laboratories Co. is a Japan-based private company founded in 1969 with 408 employees. The company operates in the medical and biological laboratory sector.

      ROSETTA GENOMICS

      Rosetta Genomics is an Israel-based public company established in 2000 with 86 employees. The company operates in the genomics and molecular diagnostics sector.

      TOSOH CORPORATION

      Tosoh Corporation is a Japan-based public company founded in 1935 with 14,850 employees. The company operates across multiple sectors including chemicals, pharmaceuticals, and diagnostics.

      DIASORIN

      DiaSorin is an Italy-based public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.

      GE HEALTHCARE

      GE Healthcare is a United States-based public company founded in 2022 with 54,000 employees. The company operates in the healthcare technology and diagnostics industry.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company operates in life sciences, diagnostics, and applied chemical markets.

      QIAGEN

      QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. The company operates in molecular diagnostics and life sciences research.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and software.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutrition.

      DANAHER

      Danaher is a United States-based public company founded in 1969 with 59,000 employees. The company operates across life sciences, diagnostics, environmental, and applied solutions sectors.

      GUARDANT HEALTH

      Guardant Health is a United States-based public company founded in 2011 with 2,498 employees. The company operates in precision oncology and liquid biopsy diagnostics.

      ILLUMINA, INC.

      Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.

      BIOMéRIEUX

      bioMérieux is a France-based public company founded in 1963 with 14,894 employees. The company operates in in vitro diagnostics and microbiology testing.

      ICON PLC

      ICON PLC is an Ireland-based public company founded in 1989 with 40,350 employees. The company provides clinical research and development services to the pharmaceutical and biotechnology industries.

      MYRIAD GENETICS, INC.

      Myriad Genetics, Inc. is a United States-based public company founded in 1991 with 2,700 employees. The company operates in molecular diagnostics and personalized medicine.

      SYSMEX CORPORATION

      Sysmex Corporation is a Japan-based public company founded in 1968 with 10,861 employees. The company operates in clinical laboratory diagnostics and life sciences.

      ABNOVA CORPORATION

      Abnova Corporation is a Taiwan-based public company founded in 2002. The company operates in the biotechnology and life sciences research sector.

      Reasons to Buy this Report

      • Market Size & Growth Trajectory : Access precise valuation data for Mexico's companion diagnostics market with detailed CAGR analysis, enabling accurate financial forecasting and investment decision-making for the 2026-2031 period.
      • Regional Competitive Intelligence : Understand Mexico's market positioning within Latin America and identify competitive opportunities specific to the Mexican healthcare landscape, regulatory environment, and reimbursement frameworks.
      • Precision Medicine Adoption Insights : Gain actionable intelligence on precision medicine adoption rates, targeted therapy utilization, and companion diagnostic penetration across Mexican oncology and specialty care segments.
      • Healthcare Investment Trends : Analyze Mexico-specific healthcare investment patterns, infrastructure development initiatives, and government policy drivers shaping companion diagnostics market expansion and accessibility.
      • Strategic Market Entry Planning : Develop informed market entry and expansion strategies for Mexico with comprehensive data on chronic disease prevalence, patient demographics, provider adoption patterns, and growth opportunities.

      Frequently asked questions

      What is the current size of Mexico's companion diagnostics market?

      Mexico's companion diagnostics market is valued at USD 117.4 million in 2026 and is expected to reach USD 163.7 million by 2031.

      What is the projected growth rate for companion diagnostics in Mexico?

      Mexico's companion diagnostics market is projected to grow at a compound annual growth rate (CAGR) of 11.4% from 2026 to 2031.

      What are the primary drivers of growth in Mexico's companion diagnostics market?

      Key growth drivers in Mexico include rising prevalence of chronic diseases, increasing healthcare investments, expanding pharmaceutical partnerships, improved diagnostic infrastructure, and enhanced reimbursement pathways for companion diagnostic tests.

      Which diagnostic technologies are gaining adoption in Mexico?

      Mexico is experiencing accelerated adoption of next-generation sequencing (NGS) and immunohistochemistry-based diagnostics as part of the broader shift toward precision medicine and personalized treatment approaches.

      How does Mexico's companion diagnostics market compare to the broader Latin American region?

      Mexico is positioned as a key growth market within Latin America's companion diagnostics landscape, reflecting broader regional trends toward personalized medicine and diagnostic-guided treatment selection.

      RESEARCH METHODOLOGY

      This study involved four major activities in estimating the current size of the companion diagnostics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

      Secondary Research

      Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology,. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global companion diagnostics market, and the findings were validated through primary research.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

      Companion Diagnostics Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The global size of the companion diagnostics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      Companion Diagnostics Market Top Down and Bottom Up Approach

      Data Triangulation

      After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

      Market Definition

      A companion diagnostic (CDx) is an in vitro diagnostic (IVD) device that is used to make biomarker assessments to identify whether a patient with certain chronic diseases, such as cancer, infectious diseases, and cardiovascular diseases, could benefit from a particular drug provides information essential for the safe and effective use of a specific therapeutic product, particularly targeted therapies and biologics. These tests help identify patients who are most likely to benefit from a treatment, may experience adverse reactions, or require therapy selection based on biomarker or molecular profiling. The market includes assay kits, reagents, instruments, software, and laboratory testing services across technologies such as polymerase chain reaction, next-generation sequencing, immunohistochemistry, and in situ hybridization, among others.

      Key Stakeholders

      • Manufacturers and Distributors of Companion Diagnostics Products
      • In Vitro Diagnostic (IVD) Companies
      • Hospital Laboratories
      • Diagnostic Laboratories
      • Diagnostics Suppliers
      • Pharmaceutical Companies
      • Research Laboratories and Academic Institutes
      • Clinical Research Organizations (CROs)
      • Research & Development (R&D) Companies
      • Academic Medical Centers/Government Research Organizations
      • Companion Diagnostics Service Providers
      • Government Associations
      • Market Research & Consulting Firms
      • Venture Capitalists & Investors

      Report Objectives

      • To define, describe, segment, and forecast the global companion diagnostics market, by product & service, technology, Indication, Sample type, Drug Class Associated with CDX, Application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall companion diagnostics market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America(US and Canada), Europe (Germany, France, the UK, Switzerland Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC and the Rest of Middle East], and Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, collaborations, expansions, and other developments
      • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the report:

      Geographical Analysis

      • Further breakdown of the Rest of Europe companion diagnostics market, by country
      • Further breakdown of the Rest of Asia Pacific companion diagnostics market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Segment Analysis

      • Cross-segment analysis

       

      Get the Full Companion Diagnostics Market Report

      Full forecast, segment splits, and company analysis for all Companion Diagnostics Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status